Literature DB >> 16315334

What is the current evidence for antigen involvement in the development of chronic lymphocytic leukemia?

Gerard Tobin1, Anders Rosén, Richard Rosenquist.   

Abstract

For many years it has been evident that B-cell chronic lymphocytic leukemia (CLL) displays preferential usage of individual immunoglobulin (Ig) variable heavy chain (V(H)) genes. The V(H)1-69 gene was the first to be reported overrepresented in a large number of CLL patients, where the V(H)1-69(+) CLL rearrangements showed characteristic molecular features, such as unmutated V(H) genes, usage of specific diversity/joining gene segments, and a longer than average complementarity determining region (CDR) 3 with certain common amino acid motifs. Also, biased usage of the V(H)3-07 and V(H)4-34 genes with specific rearrangement characteristics was reported in CLL. These findings led to the speculation that antigens could be involved during CLL development by triggering proliferation of B-cells with specific B-cell receptors (BCRs) leading to an increased risk of transforming events. Recently, we characterized a subset of CLL utilizing the V(H)3-21 gene that also displayed peculiar Ig features, e.g. very short and homologous CDR3s, predominant lambda expression and preferential V(lambda)2-14 gene usage. This V(H)3-21(+) subgroup also had poor prognosis despite the fact that two-thirds of cases carried mutated V(H) genes. Moreover, we and others have thereafter described further CLL subsets with very similar heavy and light chain gene rearrangement features. These latter findings of subsets expressing restricted BCRs have emphasized the hypothesis that antigens could play a role during the pathogenesis of CLL. Interestingly, recombinant antibodies produced from these restricted subsets showed similar cytoplasmatic reactivity within each group, thus suggesting recognition of a limited number of autoantigens. Further characterization of antigens is now necessary in order to understand their nature and exact role in CLL development. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2006        PMID: 16315334     DOI: 10.1002/hon.760

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  3 in total

Review 1.  Prognostic factors in chronic lymphocytic leukemia.

Authors:  Neil E Kay; Tait D Shanafelt
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 3.952

2.  IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope.

Authors:  Xuchu Que; George F Widhopf; Shahzada Amir; Karsten Hartvigsen; Lotte F Hansen; Douglas Woelkers; Sotirios Tsimikas; Christoph J Binder; Thomas J Kipps; Joseph L Witztum
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

3.  A tool kit for rapid cloning and expression of recombinant antibodies.

Authors:  Tihomir S Dodev; Panagiotis Karagiannis; Amy E Gilbert; Debra H Josephs; Holly Bowen; Louisa K James; Heather J Bax; Rebecca Beavil; Marie O Pang; Hannah J Gould; Sophia N Karagiannis; Andrew J Beavil
Journal:  Sci Rep       Date:  2014-07-30       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.